Florida Attorney General Sued Diabetes Drug Companies

The state filed a lawsuit against major insulin manufacturers and pharmacy benefit managers over drug pricing practices.

Updated on Sept. 22, 2026 in Diabetes

Bold flat-color editorial illustration of a capitol dome silhouette, evoking institutional policy action. — Florida Attorney General James Uthmeier has filed an antitrust lawsuit against insulin manufacturers and pharmacy benefit managers over alleged price-fixing practices. AI Illustration. Upload story photo >

Live Poll

Should major pharmaceutical manufacturers and pharmacy benefit managers face more legal action over drug prices?

Florida Attorney General James Uthmeier has filed a lawsuit against major insulin manufacturers and pharmacy benefit managers, alleging price-fixing and deceptive trade practices. The state is seeking restitution, civil penalties, and a permanent injunction against the companies.

Why it matters

The lawsuit targets entities that control the vast majority of the insulin market and prescription processing, aiming to hold them accountable for allegedly inflating prices. Officials claim these practices have significantly impacted the affordability of essential diabetes care for millions of residents.

The lawsuit names defendants that collectively supply 90% of the world's insulin and process approximately 80% of U.S. prescriptions. An estimated 2.3 million Florida adults, or 1 in 10 residents, are currently living with diagnosed diabetes.

The players

James Uthmeier

He is the Florida Attorney General who is leading the state's legal action against pharmaceutical manufacturers and pharmacy benefit managers.

Eli Lilly

This is a global pharmaceutical company named as a defendant in the Florida lawsuit regarding its role in the insulin supply chain.

Novo Nordisk

This is a pharmaceutical corporation and insulin manufacturer that has been named as a defendant in the state's antitrust and trade practices filing.

Sanofi

This is a multinational pharmaceutical company involved in insulin production that is being sued by the Florida Attorney General.

CVS Caremark

This is a major pharmacy benefit manager accused in the lawsuit of utilizing rebate aggregators to influence diabetes drug pricing.

The details

The legal action includes counts under the Florida Antitrust Act and the Florida Deceptive and Unfair Trade Practices Act. State officials allege that the companies involved utilized rebate aggregators to engage in anti-competitive behavior and manage drug pricing.

The lawsuit was announced at a news conference on Tuesday, September 22, 2026.

Health Landscape

The state's legal strategy utilizes the Florida Deceptive and Unfair Trade Practices Act as a primary mechanism to challenge the alleged anti-competitive behavior of the pharmaceutical industry. This action reflects a broader trend of state-level intervention into drug pricing and pharmacy benefit manager operations.

The legal action targets the pricing mechanisms for essential diabetes medications that affect the daily lives of 2.3 million Florida adults. Residents may see long-term changes to drug costs depending on the outcome of the restitution and injunction demands.

The takeaway

This lawsuit signals an intensifying effort by state authorities to regulate the complex financial arrangements between drug makers and benefit managers. Patients should continue to monitor their out-of-pocket costs and coordinate with healthcare providers regarding medication affordability.